Karen O&#x;Leary
Karen O&#x;Leary
Daniel J O&#x;Connor,Parker Moss,Matthew Wood et al.
Daniel J O&#x;Connor et al.
Vivek Lal,Supriya Warusavithana,Daniel Argaw Dagne et al.
Vivek Lal et al.
Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial [0.03%]
Brian G Rash,Kevin N Ramdas,Nataliya Agafonova et al.
Brian G Rash et al.
Alzheimer's disease (AD) is characterized by progressive cognitive decline, severe brain atrophy and neuroinflammation. We conducted a randomized, double-blind, placebo-controlled, parallel-group phase 2a clinical trial that tested the safe...
LILRB3 genetic variation is associated with kidney transplant failure in African American recipients [0.03%]
Zeguo Sun,Zhengzi Yi,Chengguo Wei et al.
Zeguo Sun et al.
African American (AA) kidney transplant recipients exhibit a higher rate of graft loss compared with other racial and ethnic populations, highlighting the need to identify causative factors. Here, in the Genomics of Chronic Allograft Reject...
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial [0.03%]
Raajit K Rampal,Sebastian Grosicki,Dominik Chraniuk et al.
Raajit K Rampal et al.
Janus kinase (JAK) inhibitors provide limited depth and durability of response in myelofibrosis. We evaluated pelabresib-a bromodomain and extraterminal domain (BET) inhibitor-plus ruxolitinib (a JAK inhibitor) compared with placebo plus ru...
Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial [0.03%]
Jeanne Tie,Yuxuan Wang,Serigne N Lo et al.
Jeanne Tie et al.
Early data from the DYNAMIC study of circulating tumor DNA (ctDNA)-guided adjuvant chemotherapy (ACT) versus standard approach met its primary outcome demonstrating reduced ACT use without compromising 2-year recurrence-free survival (RFS) ...
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial [0.03%]
Kohei Shitara,Yelena Y Janjigian,Jaffer Ajani et al.
Kohei Shitara et al.
First-line nivolumab-plus-chemotherapy demonstrated superior overall survival (OS) and progression-free survival versus chemotherapy for advanced gastroesophageal adenocarcinoma with programmed death ligand 1 combined positive score ≥ 5, m...
Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial [0.03%]
Jena S Tronieri,Eleanor Ghanbari,Jonathan Chevinsky et al.
Jena S Tronieri et al.
Current guidelines recommend behavioral treatment (BT) as the first intervention for patients with obesity. However, a substantial minority (35-50%) do not achieve a clinically meaningful loss of ≥5%. Anti-obesity medications (AOMs) are re...